Monoclonal Antibodies: Present and Future in the Treatment of Multiple Sclerosis (Based on the Proceedings of the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis - ECTRIMS)

Cover Page

Abstract

The development of new highly effective medications with acceptable safety profile targeted at the treatment of multiple sclerosis (MS) is one of the most important problems of modern neurology. In recent years, MS pathogenesis studies and clinical trials of new treatments enabled regulatory authorities of many countries to approve the use of monoclonal antibody pharmaceuticals. At the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), special consideration was given to natalizumab, alemtuzumab, daclizumab, ocrelizumab, rituximab, opicinumab, and ofatumumab. This publication provides an overview of the main results of the Congress. It was noted that decrease of disability rate in MS patients with a view to completely stopping disease progression is the most important objective of the use of the modern medications modifying MS course (MMMSC). Careful analysis is required to assess the long-term effects of the MMMSC and switching algorithms from the first line of MS therapy to the second one, as well as subsequent switching to the other regimens.

About the authors

Marina V. Votintseva

N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences

Email: sid@ihb.spb.ru
Russian Federation, St. Petersburg

Andrey M. Petrov

N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences

Email: sid@ihb.spb.ru
Russian Federation, St. Petersburg

Igor D. Stolyarov

N.P. Beсhtereva Institute of Human Brain of the Russian Academy of Sciences

Author for correspondence.
Email: sid@ihb.spb.ru
Russian Federation, St. Petersburg

References

  1. Multiple Sclerosis Journal. http://journals.sagepub.com/toc/msja/22/3_suppl
  2. Proceedings of the ECTRIMS Congress 2016. http://onlinelibrary.ectrims-congress.eu/ectrims
  3. Gusev E.I, Boiko A.N., Stolyarov I.D. Rasseyannyi skleroz. Spravochnik terminov. Izd. 2-e, dop. iizm. – Moscow: Zdorov'e cheloveka, 2015. – 448 p.(in Russ.)
  4. Hutchinson M, Kappos L, Calabresi P. et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J. Neurol. 2009; 256: 405-415. PMID: 19308305 doi: 10.1007/s00415-009-0093-1
  5. Thompson J., Noyes K, Dorsey E. et al. Quantitative risk-benefit analysis of natalizumab. Neurology. 2008; 71: 357-364. PMID: 18663181 doi: 10.1212/01.wnl.0000319648.65173.7a
  6. [Recommendations on the use of new drugs for the pathogenetic treatment of multiple sclerosis. Russian society of neurologists. Demyelinating diseases section]. Moscow: ROOI «Zdorov'e cheloveka», 2011. – 147 p. (in Russ.)
  7. Berger T., Elovaara I., Fredrikson S. et al. Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs. 2017; 31: 33-50. PMID: 27882532 doi: 10.1007/s40263-016-0394-8
  8. Votintseva M.V., Ivashkova E.V., Petrov A.M., Stolyarov I.D. [Placebo-controlled clinical trials in patients with multiple sclerosis: ethical aspects]. Vestnik Roszdravnadzora. 2014; 4: 48-52. (in Russ.)

Statistics

Views

Abstract: 1675

PDF (Russian): 3425

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Votintseva M.V., Petrov A.M., Stolyarov I.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies